Effect of Unani regimen in patients suffering from joint pain

A Clinical Study to evaluate the efficacy of the Munzij Mushil therapy along with Coded Unani Drugs UNIM318 and UNIM319 and dry fomentation in patients of Primary Tahajjur-e-mafasil called as Osteo Arthritis Grade I and II. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089157

Enrollment

Registered

2025-06-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M199- Osteoarthritis, unspecified site Health Condition 2: M199- Osteoarthritis, unspecified site Health Condition 3: M199- Osteoarthritis, unspecified site

Interventions

Intervention1: Munzij Mushil therapy along with Coded Unani Drugs UNIM318 and UNIM319 and dry fomentation: The enrolled patient will be admitted in IPD for 21 day and will be administered with Munzij

Eligibility

Inclusion criteria

Inclusion criteria: With or without overweight BMI 30 With clinical signs and symptoms pain swelling tenderness stiffness 30 minutes and creaking in knee joints if knees involved 4 Positive findings in Osteoarthritis Grade I and II by Radiology 5 ESR40 mm hr C reactive protein 10 mg l will be considered for inclusion in the study 6 Patient agrees to remain in study with assured co-operation in all respects till completion of the study

Exclusion criteria

Exclusion criteria: 1 R A systemic joint diseases or any other type of arthritis 2 Pregnancy lactating woman 3 Hypertension and other cardiovascular diseases 4 Diabetes and other metabolic disorders 5 Tuberculosis and other respiratory diseases 6 Gastrointestinal bypass surgery including irritable bowel syndrome 7 Renal hepatic impairment 8 History of presence of malignancy 9 History of alcohol and drug abuse 10 Epilepsy and other neurological disorders 11 Patient receiving treatment with experimental drugs within a 30 days prior to the study 12 Intra articular treatment Such that Corticosteroid or hyaluronic acid or treatment with medicine for O A in previous 3 months such that Glucosamine sulphate Chondroitin sulphate Diacerine etc 13 Arhroscopy or any knee surgery in the previous 6 months 14 Treatment with anticoagulant or history of haemophilia 15 ESR 40mm hr and CRP level 10 mg L

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms such as joint pain, swelling, difficulty in movement. Improvement in biochemical indices such as S. uric acid and CRP.Timepoint: 119 days	—

Secondary

Measure	Time frame
No significant changes in hematological & biochemical indices such as CBC LFT & KFT ensuring safety of the regimenTimepoint: At baseline 30 days 60 days & 90 days	—

Countries

India

Contacts

Public ContactMahboob Us Salam

Central Council for Research In Unani Medicine

salammehboob@gmail.com8521896528

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026